Exchange: NASDAQ·Updated 07:30 PM EST

CLYM News

News
all
press releases
Climb Bio's (CLYM) Outperform Rating Reaffirmed at Royal Bank Of Canada
Royal Bank Of Canada reissued an "outperform" rating and issued a $23.00 price objective on shares of Climb Bio in a research note on Wednesday...
MarketBeat
Climb Bio's (CLYM) Outperform Rating Reaffirmed at Royal Bank Of Canada
Royal Bank Of Canada reissued an "outperform" rating and issued a $23.00 price objective on shares of Climb Bio in a research note on Wednesday...
MarketBeat
More News
Here is how Climb Bio, Inc. (CLYM) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Zacks
Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.read more...
Benzinga
Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.
Zacks
Climb Bio (NASDAQ:CLYM) Reaches New 52-Week High Following Analyst Upgrade...
MarketBeat
BTIG Research boosted their price objective on shares of Climb Bio from $8.00 to $19.00 and gave the company a 'buy' rating in a report on Wednesday...
MarketBeat
Climb Bio (NASDAQ:CLYM) Trading 10.8% Higher - What's Next...
MarketBeat
Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion and to provide updates on development plans and timelines for its lead...
MarketBeat
JPMorgan Chase & Co. reduced its stake in Climb Bio, Inc. (NASDAQ:CLYM - Free Report) by 89.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and...
MarketBeat
Shares of Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) have been assigned an average recommendation of "Buy" from the twelve analysts that are currently covering the stock, Marketbeat reports. One...
MarketBeat

Advertisement|Remove ads.